Resonant Clinical Solutions expands with Labfish acquisition

Resonant Clinical Solutions announced its acquisition of Labfish, a Hamburg-based provider of rental laboratory equipment and in-house calibration services, broadening its European footprint and expanding capabilities across the clinical trial lifecycle.

What changed

Resonant Clinical Solutions (Resonant) has acquired Labfish, a Germany-based supplier of rental lab equipment and calibration services, along with its U.S. and U.K. affiliates. The deal extends Resonant’s Equipment & Ancillaries (E&A) offerings in Europe and adds specialized calibration capabilities to support clinical trials at a global scale. Labfish’ inventory includes scales, freezers, refrigerators, infusion pumps, monitors, and related supplies, plus kitting and calibration expertise.

Key facts

• Resonant is described as a global clinical solutions partner for life sciences.
• The acquisition includes Labfish and its U.S. and U.K. affiliates.
• Labfish specializes in rental lab equipment and in-house calibration, helping quality control and setup for clinical trials.
• The deal expands Resonant’s presence in Europe and enhances support for complex trial programs.

Who is affected

Life sciences companies and contract research organizations (CROs) that run clinical trials may gain broader access to rental equipment, ancillary supplies, and calibration services. Local teams in Europe, the U.S., and the U.K. could coordinate with the enlarged equipment and calibration network to support trial lifecycles and equipment readiness.

Practical next steps

• Organizations planning or running trials should review their equipment and calibration needs to see if integrated Labfish services could reduce sourcing steps.
• Stakeholders may contact Resonant or Labfish for information on inventory, calibration capabilities, and depot support across regions.
• Consider timelines for onboarding, including any changes to rental terms, service levels, and calibration schedules.

Limits and questions

The source material is a single press release and a local publication summary. Details such as price, exact terms of the acquisition, and operational integrations are not provided here. Readers should seek official company statements or regulatory filings for precise terms and potential regulatory impacts.

Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.